How Long Does Sorafenib — Take to Work?

Feeling worse early on is usually the side effects of sorafenib, not the cancer progressing. Fatigue, gut symptoms and skin changes on the hands and feet commonly peak in the first two to four weeks. This is uncomfortable but expected, and most people find it settles as their body adjusts and as their team fine-tunes the dose. If you experience something that feels different from the side effects you were warned about — new pain, swelling, or anything that worries you — contact your team rather than waiting for your next appointment.

There is no reliable way to tell from symptoms alone. For liver cancer, a falling AFP at your blood test can suggest the tumour is responding before imaging confirms it, and your team will monitor this if it applies to you. Symptom improvement — less pain, better appetite, more energy — can happen and is encouraging if it does, but the absence of improvement does not mean the drug is failing. The imaging at 8 to 12 weeks is the first reliable answer, and it is worth waiting for rather than drawing conclusions before then.

Your oncologist will discuss what the result means in the context of your full picture — how much growth, whether it is in one area or several, and how you have been tolerating the drug. Progression at the first scan does not automatically mean stopping sorafenib; some results are discussed in a multidisciplinary team meeting before a decision is made. If sorafenib is no longer helping, other treatment options exist, and your team will walk through what applies to your situation.

There is no fixed duration. Treatment continues for as long as sorafenib is controlling the disease and side effects are manageable. Some people take it for many months; others need a change sooner. The decision to continue, pause, or switch is made at each assessment point based on the scan result, your blood markers, and how you are tolerating the drug. Asking your oncologist what the plan looks like over the coming months is entirely reasonable and helps you plan your own life around it.

If sorafenib is working, it is actively blocking tumour growth every day you take the tablet — not only on the days you have a scan. The interval between scans is not a waiting period; it is treatment. This is one of the hardest things about living with an oral cancer drug, because there is no visible daily feedback. Keeping to your tablet schedule and attending your clinic visits are the most important things you can do in these weeks.

A brief early rise in AFP or other markers at the start of treatment does not reliably predict the outcome, and your team will not draw conclusions from a single early result. What matters more is the trajectory over the weeks and months that follow, interpreted alongside your imaging. Your team will look at the full pattern across multiple data points. If you see a number you are worried about at a blood-test visit, ask your team to explain it in context rather than searching for it online, where it will be missing the detail your team has.